Dual inhibition of tubulin and DNMT by the novel letermovir derivative H62 blocks leukemia. (PubMed, Biochem Pharmacol) - Jun 27, 2026 - "Leukemia therapy, especially myelogenous leukemias, is often challenged by an aggressive nature, high relapse rate due to dormant stem cells, side effects, and drug resistance. Additionally, H62, like the DNMT inhibitor 5-Azacytidine, suppressed β-tubulin in leukemic cells. These results suggest that the H62 compound possesses unique dual DNMT and microtubules-inhibitory activity through binding to DNMT and β-tubulin, making it a potent candidate for the treatment of myelogenous leukemias, including erythroleukemia with an unfavorable prognosis."
Journal • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • DNMT1
|
|
Anling Hu; Chunlin Wang; Fen Tian; Hongqian Zhu; Jian Gao; Jingrui Song; Kang Yang; Lei Huang; Qing Rao; Sheng Liu; Weidong Pu; Wuling Liu; Xiao Xiao; Yaacov Ben-David; Yanmei Li; Yao Tang; Yong Jian; Yubing Huang
|